Hormonal Effects on Nodular GAVE

Gastric antral vascular ectasia (GAVE) and its nodular antral gastropathy (NAG) variant is a unique lesion associated with hypergastrinemic hormonal alterations that may be compounded by concurrent proton pump inhibitor (PPI) therapy. The use of octreotide as a somatostatin analogue and its role in...

Descripción completa

Detalles Bibliográficos
Autores principales: Brijbassie, Alan, Osaimi, Abdullah Al, Powell, Steven M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051163/
https://www.ncbi.nlm.nih.gov/pubmed/27785232
http://dx.doi.org/10.4021/gr528w
_version_ 1782458030414102528
author Brijbassie, Alan
Osaimi, Abdullah Al
Powell, Steven M
author_facet Brijbassie, Alan
Osaimi, Abdullah Al
Powell, Steven M
author_sort Brijbassie, Alan
collection PubMed
description Gastric antral vascular ectasia (GAVE) and its nodular antral gastropathy (NAG) variant is a unique lesion associated with hypergastrinemic hormonal alterations that may be compounded by concurrent proton pump inhibitor (PPI) therapy. The use of octreotide as a somatostatin analogue and its role in the down regulation of variousenteric hormones has been well documented however its use in the management of NAG has not been widely reported. We herein present a case where octreotide induced gastrin down-regulation as well as PPI cessation facilitated NAG resolution.
format Online
Article
Text
id pubmed-5051163
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-50511632016-10-26 Hormonal Effects on Nodular GAVE Brijbassie, Alan Osaimi, Abdullah Al Powell, Steven M Gastroenterology Res Case Report Gastric antral vascular ectasia (GAVE) and its nodular antral gastropathy (NAG) variant is a unique lesion associated with hypergastrinemic hormonal alterations that may be compounded by concurrent proton pump inhibitor (PPI) therapy. The use of octreotide as a somatostatin analogue and its role in the down regulation of variousenteric hormones has been well documented however its use in the management of NAG has not been widely reported. We herein present a case where octreotide induced gastrin down-regulation as well as PPI cessation facilitated NAG resolution. Elmer Press 2013-04 2013-05-03 /pmc/articles/PMC5051163/ /pubmed/27785232 http://dx.doi.org/10.4021/gr528w Text en Copyright 2013, Brijbassie et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Brijbassie, Alan
Osaimi, Abdullah Al
Powell, Steven M
Hormonal Effects on Nodular GAVE
title Hormonal Effects on Nodular GAVE
title_full Hormonal Effects on Nodular GAVE
title_fullStr Hormonal Effects on Nodular GAVE
title_full_unstemmed Hormonal Effects on Nodular GAVE
title_short Hormonal Effects on Nodular GAVE
title_sort hormonal effects on nodular gave
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051163/
https://www.ncbi.nlm.nih.gov/pubmed/27785232
http://dx.doi.org/10.4021/gr528w
work_keys_str_mv AT brijbassiealan hormonaleffectsonnodulargave
AT osaimiabdullahal hormonaleffectsonnodulargave
AT powellstevenm hormonaleffectsonnodulargave

Ejemplares similares